Alivus Life Sciences Limited has informed the Exchange regarding a press release dated August 01, 2025, titled "Press Release of the Company for the First Quarter ended June 30, 2025.".
ALIVUS · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Alivus Life Sciences (formerly Glenmark Life Sciences) reported Q1FY26 revenue of Rs. 6,018 Mn, up 2.2% YoY, with EBITDA at Rs. 1,813 Mn growing 9.9% YoY. EBITDA margins expanded 210 bps to 30.1% and gross margins improved 400 bps to 55.1%, reflecting better product mix. PAT came in at Rs. 1,215 Mn (20.2% margin) and the company generated strong free cash flow of Rs. 1,000 Mn, lifting cash and short-term investments to Rs. 6,604 Mn. Growth was led by the Non-GPL business, which expanded 14.5% YoY, with India, Europe, ROW, LATAM, and Japan as key contributors. Management reaffirmed guidance of high single-digit revenue growth in FY26 with margins in the 28-30% range, and stronger momentum expected in H2FY26.
Margin expansion, robust cash generation, and a debt-free balance sheet point to solid financial health, but the modest 2.2% top-line growth may temper near-term excitement. Steady non-GPL momentum and consistent margin profile support a stable outlook for shareholders.